Themis Medicare Ltd
NSE:THEMISMED
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (3), the stock would be worth ₹166.73 (69% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.8 | ₹98.7 |
0%
|
| 3-Year Average | 3 | ₹166.73 |
+69%
|
| 5-Year Average | 1.9 | ₹105.1 |
+6%
|
| Industry Average | 3.3 | ₹187.28 |
+90%
|
| Country Average | 2.3 | ₹127.47 |
+29%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Themis Medicare Ltd
NSE:THEMISMED
|
9.1B INR | 1.8 | -52.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 8.9 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 3.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 2.6 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 1 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | -9.1 | 4 516.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.3 |
| Median | 2.3 |
| 70th Percentile | 4.2 |
| Max | 4 185.7 |
Other Multiples
Themis Medicare Ltd
Glance View
Themis Medicare Ltd. is a holding company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-04-02. The firm is focused on the formulation and active pharmaceutical ingredients (API) activity. Its product category includes star products, differential products, and APIs. Its star products include OD-LM (Levocetrizine 5 mg + Montelukast 10 mg), Medzol (Midazolam hydrochloride 1 ml, 5ml and 10 ml), Cisatra (Cisatracurium 2 mg/ml), and Aquadol (Diclofenac sodium 75mg/ml). Its differential products include Enterofizz-EL (Bacillus clausii + Electrolytes) and Etojet (Etoricoxib 90mg/ml). Its APIs products include Simvastatin, Ketamine Hcl, and Isosorbide Di Methyl Ether (THEMISOL).The Company’s manufacturing locations in India are situated at Vapi, Haridwar and Hyderabad. The firm markets in over 44 countries. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).
